| 產品名稱 |
5F12 AD3 |
| 商品貨號 |
B163796 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody reacts with a polypeptide having the sequence NH2-Ala-Pro-Pro-Arg-Leu-Ile-Cys-Asp-Ser-Arg-Val-Leu-Glu-Arg-Tyr-Leu-Leu-Glu-Ala-Lys-COOH. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with Sp2/0-Ag14 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against erythropoietin |
| Cellular Products |
immunoglobulin; monoclonal antibody; against erythropoietin |
| Comments |
Spleen cells were fused with Sp2/0-Ag14 myeloma cells. The antibody reacts with a polypeptide having the sequence NH2-Ala-Pro-Pro-Arg-Leu-Ile-Cys-Asp-Ser-Arg-Val-Leu-Glu-Arg-Tyr-Leu-Leu-Glu-Ala-Lys-COOH. |
| Complete Growth Medium |
Culture Medium: Iscove's modified Dulbecco's medium, 90%; fetal bovine serum,
10%. |
| Subculturing |
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 x 105 cells/mL and maintain between 1 X 105 and 1 X 106 cells/mL. |
| Cryopreservation |
Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO |
| Isotype |
IgG1 |
| Name of Depositor |
Amgen, Inc., Kirin-Amgen, Inc. |
| U.S. Patent Number |
|
| References |
Lin FK. DNA sequences encoding erythropoietin. US Patent 4,703,008 dated Oct 27 1987
Egrie JC. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin. US Patent 4,558,006 dated Dec 10 1985
|
